Johnson & Johnson Revises FY23 Adjusted EPS Guidance To $10.70-$10.80 Vs. Prior Guidance Of $10.60-$10.70 And Consensus Of $10.65; It Sees FY23 Sales Of $99.3B – $100.3B Vs. Prior Guidance Of $97.9B-$98.9B And Consensus Of $98.96B
Johnson & Johnson Revises FY23 Adjusted EPS Guidance To $10.70-$10.80 Vs. Prior Guidance Of $10.60-$10.70 And Consensus Of $10.65; It Sees FY23 Sales Of $99.3B – $100.3B Vs. Prior Guidance Of $97.9B-$98.9B And Consensus Of $98.96B
强生公司将2013财年调整后的每股收益指引修订至10.70美元至10.80美元之前的指导为10.60-10.70美元，共识为10.65美元；预计23财年的销售额为993亿美元——10003亿美元之前的指引为979亿美元至989亿美元，共识为989.6亿美元
Johnson & Johnson Revises FY23 Adjusted EPS Guidance To $10.70-$10.80 Vs. Prior Guidance Of $10.60-$10.70 And Consensus Of $10.65; It Sees FY23 Sales Of $99.3B â€" $100.3B Vs. Prior Guidance Of $97.9B-$98.9B And Consensus Of $98.96B
强生公司将2013财年调整后的每股收益指引修订至10.70美元至10.80美元之前的指导为10.60-10.70美元，共识为10.65美元；预计2013财年的销售额为993亿美元” 1,0003亿美元之前的指引为979亿美元至989亿美元，共识为989.6亿美元